Genmab
Genmab is a biotechnology company focused on the development of innovative antibody-based therapies for cancer and other diseases. The company aims to improve patient outcomes through cutting-edge research and development in the biotech sector.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Antibodies binding to fibroblast activation protein alpha and death receptor 4
US-12351650-B2
View DetailsMethod for producing a controlled mixture of two or more different antibodies
US-12247065-B2
View DetailsMethods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US-12246025-B2
View Details
Antibodies binding to fibroblast activation protein alpha and death receptor 4
US-12351650-B2
View DetailsMethod for producing a controlled mixture of two or more different antibodies
US-12247065-B2
View DetailsMethods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US-12246025-B2
View DetailsProducts
Proprietary antibody platform technologies
A set of antibody engineering platforms enabling bispecific antibody generation, Fc-region modulation and enhanced complement activation to create optimized therapeutic candidates.
Daratumumab
A human, CD38-targeted monoclonal antibody with a direct on-tumor and immunomodulatory mechanism of action, used as a monotherapy and in combination therapies for multiple myeloma.
GEN3018
A DuoBody bispecific antibody targeting CD3 and FLT3 for acute myeloid leukemia and myelodysplastic syndrome.
Epcoritamab
A DuoBody bispecific antibody targeting CD3 and CD20 for hematologic cancers such as DLBCL and follicular lymphoma.
GEN1106 ADC
An antibody-drug conjugate targeting SLITRK6 for advanced solid tumors.
Rinatabart Sesutecan
An antibody-drug conjugate targeting FRα for the treatment of various solid tumors and gynecologic cancers.
Proprietary antibody platform technologies
A set of antibody engineering platforms enabling bispecific antibody generation, Fc-region modulation and enhanced complement activation to create optimized therapeutic candidates.
Daratumumab
A human, CD38-targeted monoclonal antibody with a direct on-tumor and immunomodulatory mechanism of action, used as a monotherapy and in combination therapies for multiple myeloma.
GEN3018
A DuoBody bispecific antibody targeting CD3 and FLT3 for acute myeloid leukemia and myelodysplastic syndrome.
Epcoritamab
A DuoBody bispecific antibody targeting CD3 and CD20 for hematologic cancers such as DLBCL and follicular lymphoma.
GEN1106 ADC
An antibody-drug conjugate targeting SLITRK6 for advanced solid tumors.
Rinatabart Sesutecan
An antibody-drug conjugate targeting FRα for the treatment of various solid tumors and gynecologic cancers.
Services
Partnership-based discovery, preclinical development and co-development of antibody therapeutics with external biopharma organizations.
Partnership-based discovery, preclinical development and co-development of antibody therapeutics with external biopharma organizations.
Expertise Areas
- Antibody therapeutics development
- Bispecific antibody engineering
- Fc engineering and effector-function optimization
- Preclinical pharmacology and biomarker development
Key Technologies
- Monoclonal antibody discovery
- Bispecific antibody platforms (Fab-arm exchange)
- Fc-region engineering
- Antibody hexamerization for complement activation